EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of triclabendazole and its metabolite exposure on the heart‐rate–corrected QT intervals: A randomized, placebo‐ and positive‐controlled thorough QT study in healthy individuals

William T Prince, Vinay Kumar Venishetty, Jean Lecot, Kasra Shakeri-Nejad, Cathy Gray, Amanda Taylor, Ganesh R Iyer, Julia Zack

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13564 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von William T Prince und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Fluoroquinolones, Electrocardiography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triclabendazole is an effective and well‐tolerated treatment for human fascioliasis. A placebo‐ and positive‐controlled, four‐sequence by four‐period crossover study was conducted in 45 healthy participants to assess the effect of therapeutic (10 mg/kg twice daily [b.i.d.] for 1 day) and supratherapeutic (10 mg/kg b.i.d. for 3 days) oral doses of triclabendazole on corrected QT (QTc) interval prolongation. Moxifloxacin (400 mg, oral) was used as a positive control. The highest mean placebo‐corrected change from baseline in QTcF (ΔΔQTcF) on day 4 with triclabendazole was 9.2 at therapeutic dose ms and 21.7 ms at supratherapeutic dose, at 4 h postdose. The upper limit of the two‐sided 90% confidence interval exceeded 10 ms across all timepoints, except at predose timepoint on day 4 in the therapeutic group indicating that an effect of triclabendazole on cardiac repolarization could not be excluded. However, triclabendazole had no clinically significant effects on heart rate and cardiac conduction at the studied doses. In the moxifloxacin group, the mean ΔΔQTcF peak value was 13.7 ms at 3 h on day 4. The assay sensitivity was confirmed. Maximum plasma concentration of triclabendazole, sulfoxide metabolite, and sulfone metabolite occurred at ~3‐, 4‐, and 6‐h postdose, respectively. No deaths, serious adverse events, study discontinuations due to treatment‐emergent adverse events, or clinically relevant abnormalities in laboratory evaluations and vital sign values were observed. This study showed that triclabendazole had no clinically relevant effects on heart rate and cardiac conduction; however, an effect on cardiac repolarization (ΔΔQTcF >10 ms) could not be excluded.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesElectrocardiographyHumansMoxifloxacinTriclabendazoleHeart RateCross-Over StudiesDouble-Blind MethodHealthy VolunteersDose-Response Relationship, Drug

Substanzen

MoxifloxacinFluoroquinolonesTriclabendazole

Autor:innen und Institutionen

  • Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.
  • Novartis Institutes for Biomedical Research, Novartis Healthcare Private Limited, Hyderabad, India.
  • Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Novartis Institutes for Biomedical Research, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

Zitieren

APA

Prince, W. T., Venishetty, V. K., Lecot, J., Shakeri-Nejad, K., Gray, C., Taylor, A., Iyer, G. R., & Zack, J. (2023). Effects of triclabendazole and its metabolite exposure on the heart‐rate–corrected QT intervals: A randomized, placebo‐ and positive‐controlled thorough QT study in healthy individuals. Clinical and Translational Science. https://doi.org/10.1111/cts.13564

Vancouver

Prince WT, Venishetty VK, Lecot J, Shakeri-Nejad K, Gray C, Taylor A, et al. Effects of triclabendazole and its metabolite exposure on the heart‐rate–corrected QT intervals: A randomized, placebo‐ and positive‐controlled thorough QT study in healthy individuals. Clinical and Translational Science. 2023. doi:10.1111/cts.13564

BibTeX
@article{Prince2023,
  author = {Prince, William T and Venishetty, Vinay Kumar and Lecot, Jean and Shakeri-Nejad, Kasra and Gray, Cathy and Taylor, Amanda and Iyer, Ganesh R and Zack, Julia},
  title = {Effects of triclabendazole and its metabolite exposure on the heart‐rate–corrected QT intervals: A randomized, placebo‐ and positive‐controlled thorough QT study in healthy individuals},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13564}
}
Kostenlos starten →